Panorama
87 evidence topics · 21 sources
Objective
Registered study purpose and official title
Objective stated by the sponsor
Objectives of Part A and Part B across the phase 3 trials
Location and study date
Study dates in the registry
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2025-01-29” |
| Primary completion (actual) | “2026-08-13” |
| Study completion (estimated) | “2027-05” |
| First posted | “2025-02-05” |
| Last update posted | “2026-09-04” |
Registered locations
Registry status and results posting
Study centers reported by the sponsor
EU member state decision, trial start, and recruitment dates
| Member state | Decision date | Trial start | Recruitment start | Recruitment end |
|---|---|---|---|---|
| Germany | “19/02/2025” | “21/08/2025” | “04/09/2025” | “15/05/2026” |
| France | “20/02/2025” | “26/09/2025” | “22/12/2025” | “15/05/2026” |
| Czech Republic | “24/02/2025” | “20/08/2025” | “02/09/2025” | “15/05/2026” |
| Poland | “02/03/2025” | “25/09/2025” | “03/10/2025” | “15/05/2026” |
First participant dosed, January 2025
Topline results of Part A reported September 14, 2026
Topline timing: September 2026, August 2026, superseded by results reported in September 2026
Topline timing: late third quarter of 2026, April 2026, superseded in August 2026
Topline timing: second half of 2026, January 2025, superseded in April 2026
Study design
Phase 3 randomized, double-blind, placebo-controlled design with an open-label extension
Randomization ratio and the 50 µg arm
Statistical comparisons limited to 100 µg versus placebo
Registry design fields
| Field | Registry record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Triple” |
| Phase | “Phase 3” |
| Arm 1 | “Placebo Comparator: Arm 1 - Placebo” |
| Arm 2 | “Sham Comparator: Arm 2 - 50µg DT120” |
| Arm 3 | “Experimental: Arm 3 - 100µg DT120” |
Adaptive design with blinded sample size re-estimation
Blinding, central raters, and dosing session monitors
Symptom-triggered open-label treatment in Part B
Eligibility criteria
Registered inclusion and exclusion criteria
“Diagnosis of GAD per DSM-5” (opens the source at this quote in a new tab)
“Male or female aged 18 to 74” (opens the source at this quote in a new tab)
“HAM-A Total Score ≥20” (opens the source at this quote in a new tab)
“Any clinically significant unstable illness” (opens the source at this quote in a new tab)
Key inclusion and exclusion criteria for Voyage and Panorama
Amendment of the prior psychedelic use criterion
Exclusion of a current major depressive episode
Age range in the EU trial record
Treatment
Study drug and placebo in the registry
Single dose in Part A
| Arm | Part A treatment |
|---|---|
| DT120 ODT 100 µg | “DT120 ODT 100 µg” |
| DT120 ODT 50 µg | “DT120 ODT 50 µg control” |
| Placebo | “Placebo” |
| Dosing in Part A | “Single Dose” |
Dosing session monitoring and end-of-session checklist
No psychotherapy
Study outcomes
Rationale for using hamilton anxiety rating scale total score as the primary endpoint
Primary endpoint and sponsor rationale for Week 12
Registered primary outcome and HAM-A scoring
FDA guidance on a 12-week double-blind endpoint and blinded central raters
Minimal clinically important difference used in the phase 2b trial
Sponsor target product profile for the HAM-A difference
Key secondary multiplicity-controlled endpoints
Other registered secondary outcomes in Part A
Registered secondary outcomes in Part B
Statistical analysis description
Number of participants (Planned and analyzed)
Participants randomized
Enrollment in the registry
| Field | Registry record |
|---|---|
| Enrollment (actual) | “245” |
| Planned maximum in the detailed description | “The study will enroll up to 375 participants aged 18 to 74 years” |
Participants analyzed in the ITT and safety populations
Planned enrollment: target of 200 participants after blinded sample size re-estimation, April 2026, superseded in August 2026
Planned enrollment: approximately 250 participants, January 2025, superseded in April 2026
Description of analysis sets
Primary analysis population and model
Multiplicity control of key secondary endpoints
Response and remission analyses
Subgroup analyses
Part B interim analysis populations
Results
Participant disposition
Part A disposition
| Group | Randomized | ITT population | Completed Part A |
|---|---|---|---|
| DT120 ODT 100 µg | “n=96” | “100% included in ITT population” | “90% completed Part A” |
| DT120 ODT 50 µg control | “n=52” | “100% included in ITT population” | “87% completed Part A” |
| Placebo ODT | “n=97” | “100% included in ITT population” | “90% completed Part A” |
Part B disposition at the interim analysis of August 11, 2026
| Part A group | Entered Part B | Through Week 28 | Through Week 36 | Through Week 52 |
|---|---|---|---|---|
| DT120 ODT 100 µg | “n=76” | “Through Week 28 (n=35)” | “Through Week 36 (n=24)” | “Through Week 52 (n=8)” |
| DT120 ODT 50 µg control | “n=42” | “Through Week 28 (n=19)” | “Through Week 36 (n=10)” | “Through Week 52 (n=3)” |
| Placebo ODT | “n=86” | “Through Week 28 (n=43)” | “Through Week 36 (n=35)” | “Through Week 52 (n=14)” |
Baseline characteristics
Demographics and baseline characteristics, ITT population
| Characteristic | DT120 ODT 100 µg (n=96) | DT120 ODT 50 µg control (n=52) | Placebo ODT (n=97) | Overall (n=245) |
|---|---|---|---|---|
| Mean age (years) | “39.8” | “40.4” | “42.3” | “40.9” |
| Sex (% female) | “62%” | “56%” | “62%” | “60%” |
| Race (% white) | “82%” | “85%” | “84%” | “83%” |
| Baseline HAM-A score, mean (SD) | “28.3 (5.5)” | “27.7 (4.8)” | “28.0 (5.6)” | “28.0 (5.4)” |
| Baseline CGI-S score, mean (SD) | “4.7 (0.5)” | “4.7 (0.6)” | “4.7 (0.6)” | “4.7 (0.6)” |
| Past use of any psychedelic, n (%) | “11 (12%)” | “8 (15%)” | “16 (17%)” | “35 (14%)” |
| Past use of LSD, n (%) | “4 (4%)” | “4 (8%)” | “8 (8%)” | “16 (7%)” |
Disease severity, treatment history, and comorbidity, ITT population
| Characteristic | DT120 ODT 100 µg (n=96) | DT120 ODT 50 µg control (n=52) | Placebo ODT (n=97) | Overall (n=245) |
|---|---|---|---|---|
| HAM-A moderate (<24), n (%) | “20 (21%)” | “9 (17%)” | “27 (28%)” | “56 (23%)” |
| HAM-A severe (≥24), n (%) | “76 (79%)” | “43 (83%)” | “70 (72%)” | “189 (77%)” |
| No past GAD treatments, n (%) | “29 (30%)” | “14 (27%)” | “17 (18%)” | “60 (25%)” |
| One past GAD treatment, n (%) | “20 (21%)” | “15 (29%)” | “22 (23%)” | “57 (23%)” |
| Two or more past GAD treatments, n (%) | “47 (49%)” | “23 (44%)” | “58 (60%)” | “128 (52%)” |
| Comorbid MDD, n (%) | “28 (29%)” | “17 (33%)” | “25 (26%)” | “70 (29%)” |
| MADRS score, mean (SD) | “13.3 (4.4)” | “13.4 (4.5)” | “13.5 (3.9)” | “13.4 (4.2)” |
| Years since diagnosis of GAD, mean (SD) | “6.9 (7.6)” | “9.4 (11.4)” | “9.9 (8.8)” | “8.6 (9.0)” |
| Years since onset of GAD symptoms, mean (SD) | “16.4 (12.6)” | “18.2 (15.5)” | “19.1 (13.4)” | “17.8 (13.6)” |
Characteristics at Part B entry
| Characteristic | DT120 ODT 100 µg (n=62) | DT120 ODT 50 µg control (n=33) | Placebo ODT (n=68) | Total (n=163) |
|---|---|---|---|---|
| Mean age (years) | “39.5” | “42.3” | “42.8” | “41.4” |
| Sex, female (%) | “62.9%” | “51.5%” | “58.8%” | “58.9%” |
| Race (% white) | “82.3%” | “87.9%” | “83.8%” | “84.0%” |
| HAM-A score at Part B entry | “18.3” | “21.6” | “23.3” | “21.1” |
| CGI-S score at Part B entry | “3.7” | “4.0” | “4.2” | “4.0” |
Efficacy results
Primary endpoint: change in HAM-A total score at Week 12
Primary, key secondary, and other secondary endpoints
| Endpoint | DT120 ODT 100 µg | Placebo ODT | Placebo-adjusted difference |
|---|---|---|---|
| HAM-A: LS mean change at Week 12 (primary) | “-9.8” | “-4.7” | “-5.1 (p<0.0001)” |
| CGI-S: LS mean change at Week 12 (key secondary) | “-1.0” | “-0.5” | “-0.6 (p<0.0001)” |
| HAM-A: LS mean change at Week 1 (key secondary) | “-9.8” | “-4.5” | “-5.3 (p<0.0001)” |
| CGI-S: LS mean change at Day 2 (key secondary) | “-1.1” | “-0.3” | “-0.8 (p<0.0001)” |
| HAM-A response rate (≥50%) at Week 12 | “32%” | “14%” | “18% (p<0.05)” |
| HAM-A remission rate (≤7) at Week 12 | “15%” | “4%” | “12% (p<0.05)” |
| HAM-A mild or better (<16) at Week 12 | “35%” | “17%” | “19% (p<0.01)” |
Odds ratios for response, remission, and mild or better at Week 12
| Outcome at Week 12 | Odds ratio, DT120 ODT 100 µg vs placebo |
|---|---|
| Response (HAM-A ≥ 50% improvement) | “Odds ratio: 2.9” |
| Remission (HAM-A ≤ 7) | “Odds ratio: 4.2” |
| Mild or better (HAM-A < 16) | “Odds ratio: 2.6” |
Treatment guess and functional unblinding
Subgroups analyzed for HAM-A change at Week 12
“Treatment Effect Maintained Across Key Subgroups” (opens the source at this quote in a new tab)
“Less than two (n=88)” (opens the source at this quote in a new tab)
“Two or more (n=105)” (opens the source at this quote in a new tab)
“Male (n=74)” (opens the source at this quote in a new tab)
“Female (n=119)” (opens the source at this quote in a new tab)
“<22 yrs (n=135)” (opens the source at this quote in a new tab)
“>22 yrs (n=58)” (opens the source at this quote in a new tab)
Part B interim analysis: response, remission, and mild or better through Week 28
Health-related quality of life and patient-reported outcomes
Patient-reported and functional outcomes registered for Part A
Results of patient-reported outcomes
No evidence found.
Safety results
Overview of adverse events in Part A
| Adverse event | DT120 ODT 100 µg (n=96) | DT120 ODT 50 µg control (n=51) | Placebo ODT (n=97) |
|---|---|---|---|
| Any TEAE | “91 (95%)” | “49 (96%)” | “61 (63%)” |
| Mild | “51 (53%)” | “29 (57%)” | “30 (31%)” |
| Moderate | “39 (41%)” | “19 (37%)” | “29 (30%)” |
| Severe | “1 (1%)” | “1 (2%)” | “2 (2%)” |
| Any study drug-related TEAE | “90 (94%)” | “47 (92%)” | “34 (35%)” |
| Any adverse event of special interest (AESI) | “84 (88%)” | “43 (84%)” | “31 (32%)” |
| Any SAE | “2 (2%)” | “1 (2%)” | “1 (1%)” |
| Any treatment-related SAE | “0” | “0” | “0” |
| Any TEAE leading to discontinuation | “0” | “0” | “0” |
| Any TEAE leading to death | “0” | “0” | “0” |
Tolerability summary and overall TEAE rates
TEAEs with incidence of 10% or more in the 100 µg arm, on and after dosing day
Mechanism-based adverse event categories
Suicidality
Time to meet end-of-session checklist criteria
Study limitations
Summary
Panorama randomized 245 participants 2:1:2 to a single dose of DT120 ODT 100 µg (96), DT120 ODT 50 µg (52), or placebo (97), and its primary analysis compares the 100 µg arm with placebo only. The 50 µg arm was not designed or powered for statistical comparisons, so the placebo-adjusted changes of -3.5 at Week 4 and -3.6 at Week 12 in that arm, and the dose-response statements built on them, carry no hypothesis test. The primary endpoint difference of -5.1 points (d=0.64) exceeds the 2.5-point minimal clinically important difference used in the phase 2b trial and the sponsor's 4-point target product profile; in the presentation's comparison of its trials, Panorama had a pooled endpoint standard deviation of 8.4. The study had no active comparator.
The 50 µg arm was included to mitigate functional unblinding, yet 91% (50 µg) and 95% (100 µg) of participants correctly guessed assignment to drug; no placebo-arm guess rate was reported. HAM-A ratings were made by central raters blinded to treatment assignment and visit number, and FDA guidance states that functional unblinding can lead to expectation bias. The sponsor states that the results support the conclusion that the dose response is not attributable to functional unblinding.
The results come from sponsor topline disclosures (an announcement, a slide presentation, and a Form 10-Q), the registry record lists no results posted, and one author states that adoption will depend on full peer-reviewed reporting of the Voyage and Panorama topline results. These disclosures report no confidence intervals for the primary or key secondary endpoints. Response, remission, and mild-or-better rates (32% vs 14%, 15% vs 4%, 35% vs 17%) are other secondary endpoints outside the multiplicity-controlled key secondary endpoints. Subgroup analyses cover the 100 µg and placebo arms only, and the presentation states that small subgroups give unstable estimates. Patient-reported, functional, quality of life, and sexual functioning outcomes (PGI-S, WPAI-SHP, EQ-5D-5L, CSFQ-14) are registered but unreported.
Part B results come from an interim analysis as of August 11, 2026, based on partial data and subject to change, with open-label dosing and declining numbers of participants (87 at Week 12 and 27 at Week 28 in the response analysis); the 50 µg cohort was excluded for small numbers. The presentation reports two Part B denominators, 204 participants entering Part B (76, 42, and 86 by Part A group) and an extension population of 163 (62, 33, and 68), without stating how they differ. The sponsor states that Part B safety data are expected in a future presentation.
The enrolled population was 60% female and 83% white, aged 18 to 74 years, excluded a current major depressive episode, substance use disorder, and psychotic or bipolar disorder in the participant or a first-degree relative, and excluded systematic psychotherapy within 4 weeks before screening. The psychedelic use exclusion was later amended to any lifetime use; 35 participants (14%) reported past use of any psychedelic and 16 (7%) past use of LSD. Treatment history differed between arms: 60% of placebo participants and 49% of 100 µg participants had two or more past GAD treatments. Enrollment exceeded the target of 200 participants set after a blinded sample size re-estimation. The company reports approximately 32 study centers while the registry lists 36 locations. Participants were monitored for at least 8 hours on dosing day, and 94% of the 100 µg arm met end-of-session checklist criteria by hour 8. The methods report states that Definium Therapeutics funded the study and that all of its authors are company employees.